Altamira Therapeutics Announces Successful Nanoparticle-Based Delivery of Circular RNA
31. Dezember 2024 09:00 ET
|
Altamira Therapeutics Ltd
Hamilton, Bermuda, Dec. 31, 2024 (GLOBE NEWSWIRE) -- Further proof of great versatility of Altamira’s platform for extrahepatic RNA deliveryCircular mRNA significantly increasing protein expression...
Fluidigm to Participate in the Piper Sandler 33rd Annual Virtual Healthcare Conference
16. November 2021 08:30 ET
|
Fluidigm Corporation
SOUTH SAN FRANCISCO, Calif., Nov. 16, 2021 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive...
Fluidigm Announces Third Quarter 2021 Financial Results
08. November 2021 16:02 ET
|
Fluidigm Corporation
Board Undertaking Review of Range of Value-Enhancing Opportunities SOUTH SAN FRANCISCO, Calif., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq: FLDM), an innovative biotechnology...
Fluidigm Announces Conference Call and Webcast of Third Quarter 2021 Financial Results
20. Oktober 2021 08:30 ET
|
Fluidigm Corporation
SOUTH SAN FRANCISCO, Calif., Oct. 20, 2021 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive...
Fluidigm to Participate in the Cantor Virtual Global Healthcare Conference
02. September 2021 08:30 ET
|
Fluidigm Corporation
SOUTH SAN FRANCISCO, Calif., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive...
Fluidigm to Participate in UBS Genomics 2.0 and MedTech Innovations Summit
09. August 2021 11:14 ET
|
Fluidigm Corporation
SOUTH SAN FRANCISCO, Calif., Aug. 09, 2021 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive...
Fluidigm Announces Second Quarter 2021 Financial Results with Total Revenue of $31.0 Million
05. August 2021 16:05 ET
|
Fluidigm Corporation
Base business rebounds. Promising early reception to 4th generation mass cytometry instrument. Services business achieves quarterly revenue record of $6.6 million. SOUTH SAN FRANCISCO, Calif., Aug. ...
Fluidigm Announces Conference Call and Webcast of Second Quarter 2021 Financial Results
08. Juli 2021 16:01 ET
|
Fluidigm Corporation
SOUTH SAN FRANCISCO, Calif., July 08, 2021 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive...
Fluidigm Announces Virtual Mass Cytometry Webinar Investor Event on May 24, 2021, at 1:00 p.m. Eastern Time
10. Mai 2021 13:30 ET
|
Fluidigm Corporation
SOUTH SAN FRANCISCO, Calif., May 10, 2021 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive...
Fluidigm Announces First Quarter 2021 Financial Results with Total Revenue of $32.8 Million, Up 19 Percent Over Prior Year Period
06. Mai 2021 16:05 ET
|
Fluidigm Corporation
Forecasting underlying base business growth of 16–17% supported by new product innovation SOUTH SAN FRANCISCO, Calif., May 06, 2021 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM), an...